

# Amyloid-beta in Alzheimer's Disease Pathogenesis and Treatment Symposium

**Wednesday, June 3<sup>rd</sup>, 2026, from 1:00 pm – 4:00 pm**

Course Directors: Rudy Castellani, MD and Pouya Jamshidi, MD

***Note: Schedule is tentative and subject to modification.***

Time (All Times EDT):	Session
1:00 pm – 1:20 pm	<i>Welcome/Introduction</i> Rudy Castellani, MD Northwestern University, Chicago, IL
1:20 pm – 1:55 pm	<i>The Amyloid Cascade and Disease-Modifying Therapy</i> John Hardy, PhD University College London, London, UK
1:55 pm – 2:20 pm	<i>Familial AD Treatment and Pathology</i> Richard Perrin, MD, PhD Washington University, St. Louis, MO
2:20 pm – 2:30 pm	<i>Response to Evidence in Favor of a Causal Role for the Amyloid Cascade and Treatment Benefit of Anti-A<sub>B</sub> Therapy</i> George Perry, PhD University of Texas, San Antonio, San Antonio, Texas
2:30 pm – 2:45 pm	<b>BREAK</b>
2:45 pm – 3:20 pm	<i>Risk-benefit of Lecanemab and Donanemab: Analysis of the Clinical Trial and Open-label Data</i> Alberto Espay, MD, MSc University of Cincinnati, Cincinnati, OH
3:20 pm - 3:45 pm	<i>Discussion of FDA and Big Pharma</i> Journalist Jeanne Lenzer
3:45 pm – 4:00 pm	<i>Panel Discussion, questions for panelists – All Presenters</i>
4:00 pm	<i>Closing Remarks</i> Rudy Castellani, MD Northwestern University, Chicago, IL